UCB SA
18 May 2004
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR
FROM BELGIUM, CANADA, AUSTRALIA OR JAPAN.
PART ONE OF TWO
RECOMMENDED CASH OFFER FOR CELLTECH GROUP PLC
BY UCB S.A.
* Celltech's shareholders to receive 550 pence per ordinary share (equivalent to USD
19.44 per American Depositary Share) valuing the entire issued share capital of
Celltech at GBP 1,530 million
* Celltech Board unanimously recommends the Offer
* Combination of UCB and Celltech to create a biopharmaceutical leader, based on strong
and innovative R&D and a global platform for product commercialisation
* Blending of complementary skills and strong cultural fit to deliver outstanding
growth
Summary
* The boards of UCB S.A. ('UCB') and Celltech Group plc ('Celltech' or the 'Company') announce
that they have agreed the terms of a recommended cash offer by UCB for the entire issued and to
be issued share capital of Celltech either in the form of Celltech Shares or Celltech ADSs.
* The Celltech Board, which has been so advised by Morgan Stanley & Co. Limited ('Morgan Stanley')
and J.P. Morgan plc ('JPMorgan'), considers the terms of the offer (the 'Offer') to be fair and
reasonable. In providing advice to the Celltech Board, Morgan Stanley and JPMorgan have taken
into account the commercial assessments of the Celltech Board. Accordingly, the Celltech Board
unanimously intends to recommend that Celltech Shareholders accept the Offer.
* The Offer for each Celltech Share will be 550 pence in cash and the Offer for each Celltech ADS
will be 1,100 pence, equivalent to USD 19.44, in cash. The Offer will value the existing issued
share capital of Celltech at approximately GBP 1,530 million.
* The Offer will represent a premium of approximately:
- 27.8 per cent. to the middle-market closing price of 430.5 pence per Celltech Share on 17
May 2004, the last business day prior to the date of this announcement;
- 26.3 per cent. to the average middle-market closing price of 435.6 pence per Celltech Share
during the three months prior to 17 May 2004; and
- 44.7 per cent. to the average middle-market closing price of 380.1 pence per Celltech Share
during the twelve months prior to 17 May 2004.
* UCB will finance the acquisition through bank loans. It is expected that the transaction will
be earnings accretive, post synergies and before goodwill and other intangibles amortisation,
after the second full year.
* Directors of Celltech and certain members of their immediate families have irrevocably
undertaken to accept the Offer in respect of the Celltech Shares that they beneficially own and
control, representing approximately 0.18 per cent. of the existing issued share capital of
Celltech.
* UCB, headquartered in Brussels, had a turnover of approximately Euro 3 billion in 2003 and
employs over 11,500 people. Its flagship pharmaceutical business had a turnover of Euro 1.5
billion and an EBIT of Euro 397 million in 2003. Its pharmaceutical research activities employ
over 1,000 people and have a budget of Euro 244 million for 2004.
* Celltech is a leading UK based biotech company which employs some 1,900 people and had turnover
in excess of GBP 350 million in 2003. Its investment in R&D activity, which employs some 450
people, amounted to GBP 106 million in 2003. Operating profit pre exceptional items and
goodwill amounted to approximately GBP 50 million in 2003. Celltech has a broad and innovative
pipeline including a major new product in advanced phase III trials (CDP870) for which UCB has
entered into a worldwide license agreement. The license agreement is not conditional upon the
success of the proposed Offer for Celltech by UCB.
* The combination of UCB and Celltech will create a European based company which will be one of
the largest biopharmaceutical companies in the world. In a number of important areas the
combined group will benefit from a high degree of complementarity:
- Complementary product offerings: the combined group will have strong positions in specialty
therapeutic areas such as Central Nervous System (Epilepsy, Multiple Sclerosis, Parkinson's
Disease, etc.), Inflammation (Respiratory, Rheumatology, Gastro-Enterology) and Oncology;
- Strengthened research and development: the combined group will benefit from Celltech's
innovative expertise in biotechnological R&D, especially monoclonal antibodies, and UCB's
expertise in pharmaceutical chemistry. This will result in a significantly strengthened
combination of small and large molecule discovery and development expertise allowing the
combined group to increase the flow of drug development candidates;
- Stronger and broader commercial operations (US, Europe and Asia): the combined group will
be better positioned, through its enhanced global presence, to commercialise and launch new
products, particularly in the specialist areas in which the combination will focus and
where UCB has already demonstrated its ability to launch and propel products successfully
to market leadership (e.g., Keppra); and
- The blending of skills and culture, through the successful combination of competencies at
all levels of the combined entity, will accelerate innovation and profitable growth.
* A Loan Note Alternative will also be made available to Celltech Shareholders other than certain
Overseas Celltech Shareholders.
Commenting on the Offer, Dr. Peter Fellner, Chairman of Celltech, said:
'Since listing in 1993, Celltech has successfully established itself as one of
Europe's leading biotechnology companies built on a platform of internationally
respected research and excellent people. UCB recognises these strengths and
this offer represents fair value for Celltech Shareholders.'
Commenting on the Offer, Baron Georges Jacobs, Chairman of the Executive
Committee of UCB, said:
'We have pursued and implemented over the last few years an ambitious plan to
develop the company in pharmaceuticals, including through external growth. I am
therefore very pleased to announce this transaction which represents a major
step in the implementation of our goals, as well as a unique opportunity to
build a leading innovative biopharmaceutical company.'
Commenting on the Offer, Dr. Goran Ando, CEO of Celltech said:
'Celltech possesses unique and outstanding UK based research capabilities which
UCB has committed to making a cornerstone of the combined group's growth
strategy. Together, we will be one of the world's largest biopharmaceutical
companies.'
Commenting on the Offer, Roch Doliveux, CEO of UCB Pharma said:
'I am looking forward to working with Celltech's excellent management and fine
scientific teams to transform Celltech's and UCB's very promising pipeline into
commercial value for our shareholders. The new combined entity has all that it
takes to rapidly be positioned as a global leader in Neurology, especially with
Keppra and its successors, in Inflammation with CDP870, and in Allergy with
Xyzal and Zyrtec, with a strong research engine focused on validated targets to
fuel our long term growth.'
Lazard & Co., Limited ('Lazard') is acting as exclusive financial adviser to UCB
in relation to the Offer. Morgan Stanley and JPMorgan are acting as financial
advisers to Celltech in relation to the Offer. Lazard Freres & Co. LLC is
acting as dealer manager for the Offer in the United States.
In connection with the Offer, Panmure Gordon, a division of Lazard is acting as
broker to UCB.
This summary should be read in conjunction with the full text of the following
announcement. Appendix III to the following announcement contains definitions
of certain terms used in this summary and the following announcement.
There will be a presentation to analysts at 09:00 BST today in the Great Hall at
JPMorgan, 60 Victoria Embankment, London, EC4Y OJP and at 16:30 CET at UCB, 60
Allee de la Recherche, 1070 Brussels.
Interviews with Georges Jacobs, Chairman of the Executive Committee of UCB, Dr.
Roch Doliveux, CEO of UCB Pharma, and Dr. Goran Ando, CEO of Celltech, are
available on www.cantos.com and www.celltechgroup.com.
PRESS ENQUIRIES:
UCB Tel: +32 (2) 559 92 99
Roch Doliveux
Laurence Battaille
Lazard (Financial adviser to UCB)
London Tel: +44 (0)20 7187 2000
William Rucker
David Gluckman
Will Thompson
New York Tel: +1 (212) 632 6000
Stephen Sands
Jason Bernhard
Paris Tel: +33 (1) 44 13 01 11
Matthieu Bucaille
Bertrand Moulet
Brunswick Group (Media adviser to UCB)
Laurent Perpere Tel: +33 (6) 21 06 40 33
Aurelia de Lapeyrouse Tel: +33 (6) 87 80 18 13
Jon Coles Tel: +44 (0)20 7404 5959
Celltech Tel: +44 (0)1753 534 655
Goran Ando
Peter Allen
Richard Bungay
Morgan Stanley (Joint financial adviser to Celltech) Tel: +44 (0)20 7425 5000
Simon Robey
Mark Warham
JPMorgan (Joint financial adviser to Celltech) Tel: +44 (0)20 7742 4000
Bernard Taylor
Julian Oakley
Brunswick Group (Media adviser to Celltech) Tel: +44 (0)20 7404 5959
Jon Coles
Wendel Carson
Lazard is acting for UCB and no one else in connection with the Offer and will
not be responsible to anyone other than UCB for providing the protections
afforded to clients of Lazard or for providing advice in connection with the
Offer, the contents of this announcement or any transaction or arrangement
referred to herein.
Morgan Stanley is acting for Celltech and no one else in connection with the
Offer and will not be responsible to anyone other than Celltech for providing
the protections afforded to clients of Morgan Stanley or for providing advice in
connection with the Offer, the contents of this announcement or any transaction
or arrangement referred to herein.
JPMorgan is acting for Celltech and no one else in connection with the Offer and
will not be responsible to anyone other than Celltech for providing the
protections afforded to clients of JPMorgan or for providing advice in
connection with the Offer, the contents of this announcement or any transaction
or arrangement referred to herein.
This press announcement does not constitute an offer or invitation to purchase
any securities or a solicitation of an offer to buy any securities, pursuant to
the Offer or otherwise. The Offer will be made solely by means of an Offer
Document and the Acceptance Forms accompanying the Offer Document, which will
contain the full terms and conditions of the Offer, including details of how the
Offer may be accepted. In the United States, UCB will file a Tender Offer
Statement containing the Offer Document and other related documentation with the
US Securities and Exchange Commission (the 'SEC') on Schedule TO and Celltech
will file a Solicitation/Recommendation Statement with the SEC on Schedule 14D-9
on the date the Offer Document is mailed to Celltech Shareholders. Free copies
of the Schedule TO, the Schedule 14D-9 and the other related documents to be
filed by Celltech or UCB in connection with this Offer will be available from
the date the Offer Document is mailed to Celltech Shareholders on the SEC's
website at http://www.sec.gov. The Offer Document and Acceptance Forms
accompanying the Offer Document will be made available to all Celltech
Shareholders at no charge to them. Celltech Shareholders are advised to read
the Offer Document and the accompanying Acceptance Forms when they are sent to
them because they will contain important information. Celltech Shareholders in
the United States are also advised to read the Tender Offer Statement and the
Solicitation/Recommendation Statement because they will contain important
information.
It should be noted that by virtue of the conflicting provisions of the City Code
and the Exchange Act, the Panel has agreed that the Acceptance Condition can be
structured so that the Offer cannot become or be declared unconditional as to
acceptances until such time as all other conditions of the Offer have been
satisfied, fulfilled or, to the extent permitted, waived. The Acceptance
Condition in paragraph (a) of Appendix I has been amended accordingly.
Unless otherwise determined by UCB and permitted by applicable law and
regulation, the Offer (including the Loan Note Alternative) will not be made,
directly or indirectly, in or into, or by use of the mails of, or by any other
means or instrumentality (including, without limitation, telephonically or
electronically) of interstate or foreign commerce of, or of any facility of a
national securities exchange of Canada, nor will it be made in or into Belgium,
Australia or Japan and the Offer will not be capable of acceptance by any such
use, means, instrumentality or facilities or from within Belgium, Australia,
Canada or Japan. Accordingly, unless otherwise determined by UCB and permitted
by applicable law and regulation, neither copies of this announcement nor any
other documents relating to the Offer are being, or may be, mailed or otherwise
forwarded, distributed or sent in or into Belgium, Australia, Canada or Japan
and persons receiving such documents (including custodians, nominees and
trustees) must not distribute or send them in, into or from such jurisdictions.
The Loan Notes to be issued pursuant to the Loan Note Alternative have not been,
and will not be, listed on any stock exchange and have not been and will not be
registered under the Securities Act or under any relevant securities laws of any
state or other jurisdiction of the United States, or under the relevant
securities laws of Belgium, Australia, Canada or Japan or any other
jurisdiction. Accordingly, unless an exemption under such relevant laws is
available, Loan Notes may not be offered, sold, re-sold or delivered, directly
or indirectly, in, into or from the United States, Belgium, Australia, Canada or
Japan or any other jurisdiction in which an offer of Loan Notes would constitute
a violation of relevant laws or require registration of the Loan Notes, or to or
for the account or benefit of any US person or resident of Belgium, Australia,
Canada or Japan or any other such jurisdiction.
The Panel wishes to draw the attention of member firms of the New York Stock
Exchange to certain UK dealing disclosure requirements during the offer period.
The offer period (in accordance with the City Code, which is published and
administered by the Panel) commences at the time when an announcement is made of
a proposed or possible offer, with or without terms. Celltech has equity
securities traded on the London Stock Exchange and the New York Stock Exchange.
The above disclosure requirements are set out in more detail in Rule 8 of the
City Code. In particular, Rule 8 requires public disclosure of dealings during
the offer period by persons who own or control, or who would as a result of any
transaction own or control, one per cent. or more of any class of relevant
securities of the offeree company. Relevant securities include Celltech Shares,
Celltech ADSs, instruments convertible into Celltech Shares or Celltech ADSs and
options in respect of any of the foregoing and derivatives referenced to any of
the foregoing. This requirement will apply until the first closing date or, if
this is later, the date when the Offer becomes or is declared unconditional or
lapses.
Disclosure should be made on an appropriate form by no later than 12:00 noon
(London time), 7:00 a.m. (New York City time), on the business day following the
date of the dealing transaction. These disclosures should be sent a Regulatory
Information Service and a copy faxed to the Panel (+44 (0) 20 7638 1554).
The Panel requests that member firms advise those of their clients who wish to
deal in the relevant securities of Celltech, whether in the United States or in
the United Kingdom, that they may be affected by these requirements. If there
is any doubt as to their application the Panel should be consulted (telephone
number: +44 (0) 20 7382 9026, fax number: +44 (0) 20 7638 1554).
This press announcement includes 'forward-looking statements' relating to the
Offer, UCB and Celltech that are subject to known and unknown risks and
uncertainties, many of which are outside of UCB's and Celltech's control and are
difficult to predict, that may cause actual results to differ materially from
any future results expressed or implied from such forward-looking statements.
Important factors that could cause actual results to differ materially from such
expectations include, without limitation: the inability to obtain necessary
regulatory approvals in the context of the Offer or to obtain them on acceptable
terms; the inability to integrate successfully Celltech within UCB or to realise
synergies from such integration following the acquisition; costs related to the
acquisition of Celltech; the economic environment of the industries in which UCB
and Celltech operate; costs associated with research and development; changes in
the prospects for products in the research and development pipeline of UCB or
Celltech; dependence on the existing management of UCB and Celltech; changes or
uncertainties in UK or US federal or state tax laws or the administration of
such laws; changes or uncertainties in the laws or regulations applicable to the
markets in which UCB and Celltech operate, including those of the Federal Drug
Administration in the United States; and other factors detailed in Celltech's
filings with the SEC.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR
FROM BELGIUM, CANADA, AUSTRALIA OR JAPAN.
PART TWO OF TWO
RECOMMENDED CASH OFFER FOR CELLTECH GROUP PLC
BY UCB S.A.
1. Introduction
The boards of UCB and Celltech announce that they have agreed the terms of a recommended
cash offer, to be made by UCB, and outside the United States, by Lazard on its behalf, for
the entire issued and to be issued share capital of Celltech either in the form of Celltech
Shares or Celltech ADSs. The Offer for each Celltech Share will be 550 pence in cash. This
represents 1,100 pence for each Celltech ADS (each Celltech ADS representing two Celltech
Shares). The Offer will value the existing issued share capital of Celltech at
approximately GBP 1,530 million.
The Celltech Board, which has been so advised by Morgan Stanley and JPMorgan, considers the
terms of the Offer to be fair and reasonable. In providing advice to the Celltech Board,
Morgan Stanley and JPMorgan have taken into account the commercial assessments of the
Celltech Board. Accordingly, the Celltech Board unanimously intends to recommend that
Celltech Shareholders accept the Offer.
Directors of Celltech and certain members of their immediate families have irrevocably
undertaken to accept the Offer in respect of the Celltech Shares that they beneficially own
and control, amounting in aggregate to 493,029 Celltech Shares, representing approximately
0.18 per cent. of the existing issued share capital of Celltech.
Lazard is acting as exclusive financial adviser to UCB in relation to the Offer. Morgan
Stanley and JPMorgan are acting as financial advisers to Celltech in relation to the Offer.
2. The Offer
UCB and (outside of the United States) Lazard, on behalf of UCB, will offer to acquire, on
the terms and subject to the conditions set out below and in Appendix I of this
announcement, and to be set out in the Offer Document and the Acceptance Forms, all of the
Celltech Shares and Celltech ADSs.
The Offer will be made on the following basis:
for each Celltech Share 550 pence in cash
for each Celltech ADS 1,100 pence (equivalent to USD 19.44) in
cash
The Offer will value the existing issued share capital of Celltech at approximately GBP
1,530 million.
The Offer will represent a premium of approximately:
- 27.8 per cent. to the middle-market closing price of 430.5 pence per Celltech Share
on 17 May 2004, the last business day prior to the date of this announcement;
- 26.3 per cent. to the average middle-market closing price of 435.6 pence per
Celltech Share during the three months prior to 17 May 2004; and
- 44.7 per cent. to the average middle-market closing price of 380.1 pence per
Celltech Share during the twelve months prior to 17 May 2004.
The Celltech Shares (including those represented by Celltech ADSs) will be acquired pursuant
to the Offer fully paid and free from all liens, charges, equitable interests, encumbrances,
rights of pre-emption and any other rights and interests of any nature whatsoever and
together with all rights now and hereafter attaching thereto, including voting rights and
the right to receive and retain in full all dividends and other distributions (if any)
declared, made or paid on or after the date of this announcement.
The Offer Document will be sent to Celltech Shareholders shortly. The Offer will be on the
terms and will be subject to the conditions which are set out in Appendix I and to those
terms which will be set out in the Offer Document and in the accompanying Acceptance Forms,
and such further terms as may be required to comply with the rules and regulations of the
Financial Services Authority, the United Kingdom Listing Authority, The London Stock
Exchange and with the City Code and US federal securities laws (except to the extent of any
exemptive relief granted by the SEC).
3. Loan Note Alternative
Celltech Shareholders (other than certain Overseas Celltech Shareholders, including Celltech
Shareholders in the United States) who validly accept the Offer will be entitled to elect to
receive Loan Notes to be issued by UCB instead of some or all of the cash consideration to
which they would otherwise be entitled pursuant to the Offer.
The Loan Note Alternative will be made available on the following basis:
for every whole GBP 1 in cash GBP 1 nominal value of Loan Notes
consideration
The Loan Notes, which will be governed by English law, will be unsecured and will be issued
credited as fully paid in amounts and integral multiples of GBP 1 nominal value. All
fractional entitlements to the Loan Notes will be disregarded. No application will be made
for the Loan Notes to be listed or dealt in on any stock exchange.
The Loan Notes will bear interest at 0.75 per cent. below six-month sterling LIBOR.
Interest will be payable by six-monthly instalments in arrears (less any tax required to be
withheld) on 31 March and 30 September in each year. The first payment of interest will be
made on 31 March 2005 (the 'First Payment Date'). On the First Payment Date, interest will
be paid in respect of the period from (and including) the first date of issue of the Loan
Notes to (but excluding) the First Payment Date. The Loan Notes will be redeemable in whole
or in part for cash at the option of noteholders on 31 March 2005 and on subsequent interest
payment dates. In certain circumstances, UCB will have the right to redeem all of the Loan
Notes. If not previously redeemed, all outstanding Loan Notes will be redeemed on 30
September 2010.
No Loan Notes will be issued unless, on or before the date on which the Offer becomes or is
declared unconditional in all respects, valid elections have been received in respect of at
least GBP 5 million in nominal value of Loan Notes. If insufficient elections are received,
Celltech Shareholders electing for the Loan Note Alternative will instead receive cash in
accordance with the terms of the Offer.
Subject as aforesaid, the Loan Note Alternative will remain open for acceptance for so long
as the Offer remains open for acceptance. The Loan Note Alternative will be conditional
upon the Offer becoming or being declared unconditional in all respects.
Celltech Shareholders and holders of Celltech ADSs who are not resident in the United
Kingdom should refer to paragraph 14 below.
Further details of the Loan Notes will be contained in the Offer Document.
4. Irrevocable Undertakings to accept the Offer
UCB has received irrevocable undertakings to accept the Offer from Directors of Celltech and
certain members of their immediate families in respect of, in aggregate, 493,029 Celltech
Shares, representing all of the Celltech Shares beneficially owned and controlled by the
Directors and such family members. This represents approximately 0.18 per cent. of the
existing issued share capital of Celltech. Such undertakings cease to be binding only if
the Offer lapses or is withdrawn.
5. Background to and reasons for the Offer
The combination of UCB and Celltech will create a European based company which will be one
of the largest biopharmaceutical companies in the world. In a number of important areas the
combined group will benefit from a high degree of complementarity:
- Complementary product offerings: the combined group will have strong positions in
specialty therapeutic areas such as Central Nervous System (Epilepsy, Multiple
Sclerosis, Parkinson's Disease, etc.), Inflammation (Respiratory, Rheumatology,
Gastro-Enterology) and Oncology;
- Strengthened research and development: the combined group will benefit from Celltech's
innovative expertise in biotechnological R&D, especially monoclonal antibodies, and
UCB's expertise in pharmaceutical chemistry. This will result in a significantly
strengthened combination of small and large molecule discovery and development expertise
allowing the combined group to increase the flow of drug development candidates;
- Stronger and broader commercial operations (US, Europe and Asia): the combined group
will be better positioned, through its enhanced global presence, to commercialise and
launch new products, particularly in the specialist areas in which the combination will
focus and where UCB has already demonstrated its ability to launch and propel products
successfully to market leadership (e.g., Keppra); and
- The blending of skills and culture, through the successful combination of competencies
at all levels of the combined entity, will accelerate innovation and profitable growth.
The combined R&D operations of the Group will have their headquarters in Slough, UK.
Dr. Goran Ando will be deputy CEO of the combined group and Peter Allen will be in charge of
integration.
As separately announced today, UCB and Celltech have entered into a co-exclusive worldwide
collaboration agreement for the research, development and commercialisation of CDP870,
Celltech's anti-TNF-alpha PEGylated antibody fragment, for all indications outside of
Crohn's disease in North America and major European markets.
6. Financial Effects of the Transaction
UCB will finance the acquisition through bank loans. It is expected that the transaction
will be earnings accretive, post synergies and before goodwill and other intangibles
amortisation, after the second full year.
7. Information on Celltech
Celltech is one of the largest European-based biopharmaceutical companies, possessing
significant discovery and development capabilities, a broad product pipeline, and an
international pharmaceutical business, with operations in the United States and Europe. It
derives revenues from the licensing of its technologies and products and the sale of
pharmaceutical products through its pharmaceutical business.
The discovery and development activities are focused on treatments for auto-immune and
inflammatory disorders and oncology. Its pipeline includes candidates comprising new
chemical entities and antibody-based therapeutics, in pre-clinical or clinical development
and marketing licence registration. Its technology base includes a leading position in
antibody engineering and extensive medicinal chemistry capabilities. Celltech has a range
of discovery, development and commercialisation collaborations with leading pharmaceutical
and biotechnology companies including: Abgenix, Amgen, AstraZeneca, Biogen Idec, Johnson &
Johnson, Merck, NeoGenesis, Seattle Genetics and Wyeth.
Celltech Shares are traded on the London Stock Exchange and Celltech ADSs are listed on the
New York Stock Exchange. Cazenove & Co. Limited act as broker to Celltech.
For the year ended 31 December 2003, in accordance with generally accepted accounting
principles in the United Kingdom, Celltech reported turnover of GBP 353.3 million (2002: GBP
329.6 million) with operating profit pre exceptional items and goodwill of GBP 49.5 million
(2002: GBP 49.0 million) and net assets of GBP 505.9 million (2002: GBP 564.4 million).
8. Information on UCB
UCB is a world-class pharmaceutical and specialty chemical company. UCB is headquartered
in Brussels (Belgium) and employs about 11,500 people, of whom more than 6,600 are in the
pharmaceutical sector.
UCB operates in two industrial sectors: Pharma and Surface Specialties. It currently
comprises the parent company, UCB S.A., together with about 120 subsidiaries and associated
companies in Europe, the Americas and Asia. UCB also operates on a worldwide basis through
its agents, distributors and licensees.
The Pharma Sector researches, produces and markets prescription medical products,
particularly in the fields of allergy / asthma and neurology. Over three quarters of the
UCB Group's expenditure on research and development is in the Pharma Sector, where it
accounts for about 15 per cent. of turnover. UCB is also present in biotechnology, through
UCB-Bioproducts, making available peptides by extraction or synthesis to the scientific
community.
Surface Specialties is focused on the manufacture of technically innovative products and
solutions for surface applications. There are two business units: Coating Resins &
Additives and Films & Adhesives.
UCB's shares are traded on Euronext. Based on the closing middle-market price of Euro 35.10
per UCB Share on 17 May 2004 (the last business day prior to the date of this announcement),
UCB has a market capitalisation of approximately Euro 5.1 billion.
For the year ended 31 December 2003, in accordance with generally accepted accounting
principles in Belgium, UCB reported group turnover of Euro 2,966 million (2002: Euro 2,514
million) with group profit before interest, tax and exceptional items of Euro 487 million
(2002: Euro 503 million) and net assets of Euro 1,784 million (2002: Euro 1,565 million).
9. Management and Employees
The board of UCB confirms that, following the Offer becoming or being declared unconditional
in all respects, the existing employment rights, including pension rights, of all employees
of the Celltech Group will be fully safeguarded.
10. Celltech Share Plans
The Offer will (subject to compliance with any applicable local law) extend to any Celltech
Shares issued fully paid (or credited as fully paid) or unconditionally allotted or issued
prior to the date when the Offer closes (or such earlier date as UCB may, subject to the
provisions of the City Code or with the consent of the Panel, decide) as a result of the
exercise of options granted under the Celltech Share Plans.
As soon as practicable after the Offer becomes or is declared unconditional in all respects,
UCB will make appropriate proposals (taking into account any local laws) to holders of
options granted under the Celltech Share Plans.
11. Inducement Fee
Celltech has agreed to pay a sum to UCB of GBP 15.25 million (being approximately one per
cent. of the value of the Offer) in the event that (a) the Directors withdraw their
unanimous recommendation of the Offer or recommend an alternative transaction, resulting in
any person other than UCB (or any person acting in concert with UCB as defined in the City
Code) acquiring control of Celltech (as defined in the City Code) or a substantial part of
the business of Celltech; or (b) before the Offer lapses or is withdrawn without becoming or
being declared wholly unconditional, any person (other than UCB or a person acting in
concert (as defined in the City Code) with UCB) announces an intention to make a competing
offer however effected, to acquire the entire issued share capital of Celltech (other than
Celltech Shares owned by such third party or persons acting in concert with it) and, at any
time, the competing offer becomes or is declared wholly unconditional.
12. Compulsory acquisition, delisting and de-registration
If UCB receives acceptances under the Offer in respect of, and/or otherwise acquires, 90 per
cent. or more of the Celltech Shares to which the Offer relates and the Offer becomes or is
declared unconditional in all respects, UCB intends to exercise its rights pursuant to the
provisions of sections 428 to 430F (inclusive) of the Act to acquire compulsorily the
remaining Celltech Shares to which the Offer relates.
After the Offer becomes or is declared unconditional in all respects, UCB intends to procure
the making of an application by Celltech to the UK Listing Authority for the cancellation of
the listing of Celltech's Shares on the Official List and to the London Stock Exchange for
the cancellation of the admission to trading of Celltech's Shares on its market for listed
securities. It is anticipated that cancellation of listing and trading will take effect no
earlier than 20 business days after the Offer becomes or is declared unconditional in all
respects. UCB also intends to procure that Celltech applies for delisting of the Celltech
ADSs from the New York Stock Exchange. Such delistings would significantly reduce the
liquidity and marketability of any Celltech Shares or Celltech ADSs not tendered into the
Offer. UCB may also request that Celltech terminate the existing deposit agreement through
which the ADS programme is operated.
It is also proposed that, following the Offer becoming or being declared unconditional in
all respects and after the Celltech Shares are delisted, Celltech will be re-registered as a
private company under the relevant provisions of the Act.
13. Disclosure of Interests in Celltech
Save for the 493,029 Celltech Shares in respect of which UCB has received irrevocable
undertakings to accept the Offer, neither UCB nor any of the directors of UCB nor any other
UCB subsidiary, nor, so far as UCB is aware, any person acting in concert with UCB for the
purposes of the Offer, owns, controls or holds any Celltech Shares or any securities
convertible or exchangeable into, or rights to subscribe for, purchase or holds any options
to purchase any Celltech Shares or has entered into any derivative referenced to Celltech
Shares which remains outstanding.
14. Overseas Celltech Shareholders
The availability of the Offer to persons not resident in the United Kingdom may be affected
by the laws of the relevant jurisdiction. Persons who are not resident in the United
Kingdom should inform themselves about and observe any applicable requirements.
Under the terms of the Offer, holders of Celltech Shares and holders of Celltech ADSs who
are located in Belgium, Canada, Australia, Japan or the United States or who are US persons
will not be eligible to receive Loan Notes.
Notwithstanding the foregoing, UCB retains the right to permit the Offer to be accepted and
any sale of securities pursuant to the Offer to be completed if, in its sole discretion, it
is satisfied that the transaction in question can be undertaken in compliance with
applicable law and regulation.
Lazard Freres & Co. LLC is acting as the dealer manager for the Offer in the United States.
15. Collaboration Agreement
Celltech has announced today that it has entered into an agreement with UCB for the
worldwide development and marketing of CDP870, Celltech's anti-TNF-alpha PEGylated antibody
fragment.
Under the terms of the agreement, Celltech grants UCB co-exclusive worldwide rights to
develop and commercialise CDP870. The license is exclusive for rheumatoid arthritis and
other indications, excluding Crohn's disease. UCB will be responsible for the conduct of
future clinical studies and all commercialisation activities with CDP870 other than in
Crohn's disease, and will pay Celltech a significant royalty on sales in these indications.
UCB will also make progress-related payments to Celltech dependent upon attaining certain
project related milestones. Celltech retains manufacturing rights and will supply all
CDP870 material for commercialisation, and will discharge all royalties due to third
parties. Celltech retains exclusive rights for the development and commercialisation of
CDP870 in Crohn's disease in North America, major European markets, Australia and New
Zealand with UCB having development and commercialisation rights in other territories.
The CDP870 license agreement is not conditional upon the success of the proposed Offer for
Celltech by UCB.
General
The Offer will be made on the terms and subject to the conditions set out herein and in Appendix
I, and to be set out in the Offer Document and the accompanying Acceptance Forms. These will be
despatched to Celltech Shareholders and holders of Celltech ADSs and for information only, to
participants in the Celltech Share Schemes, in due course. The Offer and acceptances thereof will
be governed by English law. The Offer will be subject to the applicable requirements of the City
Code, the Panel, the London Stock Exchange, the UK Listing Authority and the Exchange Act.
The availability of the Offer to persons not resident in the United Kingdom or the United States
may be affected by the laws of the relevant jurisdictions. Such persons should inform themselves
of, and observe, any applicable requirements.
Details of the sources and bases of certain information set out in this announcement are included
in Appendix II. Certain terms used in this announcement are defined in Appendix III.
The Offer will be made by UCB and (outside the United States) by Lazard on its behalf.
In connection with the Offer, Panmure Gordon, a division of Lazard is acting as broker to UCB.
Celltech confirms that its current issued share capital (including those represented by Celltech
ADSs) comprises 278,128,673 ordinary shares of 50 pence each. The International Securities
Identification Number for Celltech Shares is GB0001822765. There are 2,919,709 Celltech ADSs in
issue, each Celltech ADS representing two Celltech Shares. The International Securities
Identification Number for Celltech ADSs is US1511581027.
PRESS ENQUIRIES:
UCB Tel: +32 (2) 559 92 99
Roch Doliveux
Laurence Battaille
Lazard (Financial adviser to UCB)
London Tel: +44 (0)20 7187 2000
William Rucker
David Gluckman
Will Thompson
New York Tel: +1 (212) 632 6000
Stephen Sands
Jason Bernhard
Paris Tel: +33 (1) 44 13 01 11
Matthieu Bucaille
Bertrand Moulet
Brunswick Group (Media adviser to UCB)
Laurent Perpere Tel: +33 (6) 21 06 40 33
Aurelia de Lapeyrouse Tel: +33 (6) 87 80 18 13
Jon Coles Tel: +44 (0)20 7404 5959
Celltech Tel: +44 (0)1753 534 655
Goran Ando
Peter Allen
Richard Bungay
Morgan Stanley (Joint financial adviser to Celltech) Tel: +44 (0)20 7425 5000
Simon Robey
Mark Warham
JPMorgan (Joint financial adviser to Celltech) Tel: +44 (0)20 7742 4000
Bernard Taylor
Julian Oakley
Brunswick Group (Media adviser to Celltech) Tel: +44 (0)20 7404 5959
Jon Coles
Wendel Carson
Lazard is acting for UCB and no one else in connection with the Offer and will
not be responsible to anyone other than UCB for providing the protections
afforded to clients of Lazard or for providing advice in connection with the
Offer, the contents of this announcement or any transaction or arrangement
referred to herein.
Morgan Stanley is acting for Celltech and no one else in connection with the
Offer and will not be responsible to anyone other than Celltech for providing
the protections afforded to clients of Morgan Stanley or for providing advice in
connection with the Offer, the contents of this announcement or any transaction
or arrangement referred to herein.
JPMorgan is acting for Celltech and no one else in connection with the Offer and
will not be responsible to anyone other than Celltech for providing the
protections afforded to clients of JPMorgan or for providing advice in
connection with the Offer, the contents of this announcement or any transaction
or arrangement referred to herein.
This press announcement does not constitute an offer or invitation to purchase
any securities or a solicitation of an offer to buy any securities, pursuant to
the Offer or otherwise. The Offer will be made solely by means of an Offer
Document and the Acceptance Forms accompanying the Offer Document, which will
contain the full terms and conditions of the Offer, including details of how the
Offer may be accepted. In the United States, UCB will file a Tender Offer
Statement containing the Offer Document and other related documentation with the
SEC on Schedule TO and Celltech will file a Solicitation/Recommendation
Statement with the SEC on Schedule 14D-9 on the date the Offer Document is
mailed to Celltech Shareholders. Free copies of the Schedule TO, the Schedule
14D-9 and the other related documents to be filed by Celltech or UCB in
connection with this Offer will be available from the date the Offer Document is
mailed to Celltech Shareholders on the SEC's website at http://www.sec.gov. The
Offer Document and Acceptance Forms accompanying the Offer Document will be made
available to all Celltech Shareholders at no charge to them. Celltech
Shareholders are advised to read the Offer Document and the accompanying
Acceptance Forms when they are sent to them because they will contain important
information. Celltech Shareholders in the United States are also advised to
read the Tender Offer Statement and the Solicitation/Recommendation Statement
because they will contain important information.
It should be noted that by virtue of the conflicting provisions of the City Code
and the Exchange Act, the Panel has agreed that the Acceptance Condition can be
structured so that the Offer cannot become or be declared unconditional as to
acceptances until such time as all other conditions of the Offer have been
satisfied, fulfilled or, to the extent permitted, waived. The Acceptance
Condition in paragraph (a) of Appendix I has been amended accordingly.
Unless otherwise determined by UCB and permitted by applicable law and
regulation, the Offer (including the Loan Note Alternative) will not be made,
directly or indirectly, in or into, or by use of the mails of, or by any other
means or instrumentality (including, without limitation, telephonically or
electronically) of interstate or foreign commerce of, or of any facility of a
national securities exchange of Canada, nor will it be made in or into Belgium,
Australia or Japan and the Offer will not be capable of acceptance by any such
use, means, instrumentality or facilities or from within Belgium, Australia,
Canada or Japan. Accordingly, unless otherwise determined by UCB and permitted
by applicable law and regulation, neither copies of this announcement nor any
other documents relating to the Offer are being, or may be, mailed or otherwise
forwarded, distributed or sent in or into Belgium, Australia, Canada or Japan
and persons receiving such documents (including custodians, nominees and
trustees) must not distribute or send them in, into or from such jurisdictions.
The Loan Notes to be issued pursuant to the Loan Note Alternative have not been,
and will not be, listed on any stock exchange and have not been and will not be
registered under the Securities Act or under any relevant securities laws of any
state or other jurisdiction of the United States, or under the relevant
securities laws of Belgium, Australia, Canada or Japan or any other
jurisdiction. Accordingly, unless an exemption under such relevant laws is
available, Loan Notes may not be offered, sold, re-sold or delivered, directly
or indirectly, in, into or from the United States, Belgium, Australia, Canada or
Japan or any other jurisdiction in which an offer of Loan Notes would constitute
a violation of relevant laws or require registration of the Loan Notes, or to or
for the account or benefit of any US person or resident of Belgium, Australia,
Canada or Japan or any other such jurisdiction.
The Panel wishes to draw the attention of member firms of the New York Stock
Exchange to certain UK dealing disclosure requirements during the offer period.
The offer period (in accordance with the City Code, which is published and
administered by the Panel) commences at the time when an announcement is made of
a proposed or possible offer, with or without terms. Celltech has equity
securities traded on the London Stock Exchange and the New York Stock Exchange.
The above disclosure requirements are set out in more detail in Rule 8 of the
City Code. In particular, Rule 8 requires public disclosure of dealings during
the offer period by persons who own or control, or who would as a result of any
transaction own or control, one per cent. or more of any class of relevant
securities of the offeree company. Relevant securities include Celltech Shares,
Celltech ADSs, instruments convertible into Celltech Shares or Celltech ADSs and
options in respect of any of the foregoing and derivatives referenced to any of
the foregoing. This requirement will apply until the first closing date or, if
this is later, the date when the Offer becomes or is declared unconditional or
lapses.
Disclosure should be made on an appropriate form by no later than 12:00 noon
(London time), 7:00 a.m. (New York City time), on the business day following the
date of the dealing transaction. These disclosures should be sent to a
Regulatory Information Service and a copy faxed to the Panel (+44 (0) 20 7638
1554).
The Panel requests that member firms advise those of their clients who wish to
deal in the relevant securities of Celltech, whether in the United States or in
the United Kingdom, that they may be affected by these requirements. If there
is any doubt as to their application the Panel should be consulted (telephone
number: +44 (0) 20 7382 9026, fax number: +44 (0) 20 7638 1554).
The directors of UCB accept responsibility for the information contained in this
announcement, other than that relating to the Celltech Group, the directors of
Celltech and their immediate families, related trusts and persons connected with
them, for which the directors of Celltech accept responsibility as set out
below. To the best of the knowledge and belief of the directors of UCB (who
have taken all reasonable care to ensure that such is the case), the information
contained in this announcement for which they are responsible is in accordance
with the facts and does not omit anything to affect the import of such
information.
The directors of Celltech accept responsibility for the information contained in
this announcement relating to the Celltech Group, themselves and their immediate
families, related trusts and persons connected with them. To the best of the
knowledge and belief of the directors of Celltech (who have taken all reasonable
care to ensure that such is the case), the information contained in this
announcement for which they are responsible is in accordance with the facts and
does not omit anything likely to affect the import of such information.
This press announcement includes 'forward-looking statements' relating to the
Offer, UCB and Celltech that are subject to known and unknown risks and
uncertainties many of which are outside of UCB's and Celltech's control and are
difficult to predict, that may cause actual results to differ materially from
any future results expressed or implied from such forward-looking statements.
Important factors that could cause actual results to differ materially from such
expectations include, without limitation: the inability to obtain necessary
regulatory approvals in the context of the Offer or to obtain them on acceptable
terms; the inability to integrate successfully Celltech within UCB or to realise
synergies from such integration following the acquisition; costs related to the
acquisition of Celltech; the economic environment of the industries in which UCB
and Celltech operate; costs associated with research and development; changes in
the prospects for products in the research and development pipeline of UCB or
Celltech; dependence on the existing management of UCB and Celltech; changes or
uncertainties in UK or US federal or state tax laws or the administration of
such laws; changes or uncertainties in the laws or regulations applicable to the
markets in which UCB and Celltech operate, including those of the Federal Drug
Administration in the United States; and other factors detailed in Celltech's
filings with the SEC.
APPENDIX I
CONDITIONS AND CERTAIN FURTHER TERMS OF THE OFFER
The Offer will be subject to the following conditions:
(a) valid acceptances of the Offer being received (and not, where permitted, withdrawn) by
3.00 p.m. (London time), 10.00 a.m. (New York City time) on the twentieth US business day
following the posting of the Offer Document or such later time(s) and/or date(s) as UCB
may, subject to the rules of the City Code and in accordance with the Exchange Act,
decide in respect of not less than 90 per cent. in nominal value (or such lesser
percentage as UCB may decide) of the Celltech Shares (including Celltech Shares
represented by Celltech ADSs) to which the Offer relates, provided that this condition
will not be satisfied unless UCB and/or any of its wholly-owned subsidiaries shall have
acquired, or agreed to acquire, pursuant to the Offer or otherwise, Celltech Shares
(including Celltech Shares represented by Celltech ADSs) carrying, in aggregate more than
50 per cent. of the voting rights normally exercisable at a general meeting of Celltech,
including for this purpose (to the extent, if any, required by the Panel) any such voting
rights attaching to any Celltech Shares (including Celltech Shares represented by
Celltech ADSs) that are unconditionally allotted or issued before the Offer becomes or is
declared unconditional as to acceptances whether pursuant to the exercise of any
outstanding subscription or conversion rights or otherwise, and for the purposes of this
condition:
(i) Celltech Shares (including Celltech Shares represented by Celltech ADSs) which
have been unconditionally allotted but not issued shall be deemed to carry the
voting rights they will carry on issue;
(ii) the expression 'Celltech Shares (including Celltech Shares represented by
Celltech ADSs) to which the Offer relates' shall be construed in accordance with
sections 428 to 430F of the Companies Act; and
(iii) valid acceptances also shall be treated as having been received in respect of
any Celltech Shares (including Celltech Shares represented by Celltech ADSs)
which UCB shall, pursuant to section 429(8) of the Companies Act, be treated as
having acquired or contracted to acquire by virtue of acceptance of the Offer;
provided further that unless UCB otherwise determines, this condition (a) shall be
capable of being satisfied only at a time when all of the other conditions (b) to (m)
inclusive have been either satisfied, fulfilled or, to the extent permitted, waived;
(b) subject to condition (e) below:
(i) the UK Office of Fair Trading ('OFT') indicating in terms reasonably
satisfactory to UCB that it does not believe that the proposed acquisition of
Celltech by UCB (the 'Transaction') creates a relevant merger situation within
the meaning of section 23 of the Enterprise Act 2002 ('EA'); or
(ii) the OFT indicating in terms reasonably satisfactory to UCB that it has decided
not to refer the Transaction or any part of it to the Competition Commission
('CC'); or
(iii) the period for considering any merger notice given to the OFT under section 96
of the EA by UCB having expired without any such reference being made, provided
that sections 100(1)(a), (d) and (f) of the EA do not apply in relation to such
merger;
(c) subject to condition (e) below, UCB obtaining an approval, or being deemed to have
obtained an approval, from the German competition authority, the Federal Cartel Office
('Bundeskartellamt'), in terms reasonably satisfactory to UCB, in relation to the
Transaction;
(d) subject to condition (e) below, if the Transaction requires notification to the Austrian
Cartel Court under the Austrian Cartel Act ('Cartel Act'), then:
(i) the Austrian Cartel Court issuing a clearance certificate pursuant to Section
42b (1) Cartel Act, in terms reasonably satisfactory to UCB; or
(ii) the four week period under Section 42b (1) Cartel Act expiring without an
in-depth investigation having been opened or requested; or
(iii) the Austrian Cartel Court not prohibiting the Transaction within a period of
five months from the receipt of the complete notification; or
(iv) the Austrian Cartel Court issuing a final order pursuant to Section 42b (2) no 1
Cartel Act which sets forth that the Transaction does not constitute a
concentration within the meaning of Section 41 Cartel Act; or
(v) the Austrian Cartel Court issuing a final order pursuant to Section 42b (2) no 3
Cartel Act which sets forth, in terms reasonably satisfactory to UCB, that the
concentration will not be prohibited;
(e) if a request to the European Commission is made by the competent authorities of one or
more Member States under Article 22 of Council Regulation (EC) No 139/2004 (the
'Regulation') in relation to the Transaction or any part of it and is accepted by the
European Commission:
(i) the European Commission issuing a decision pursuant to Article 6(1)(b) of the
Regulation in terms reasonably satisfactory to UCB declaring that the
Transaction or, if applicable, the relevant part of the Transaction, is
compatible with the common market; and
(ii) to the extent that the OFT retains jurisdiction over any part of the
Transaction, one of the conditions set out in conditions (b)(i) to (iii) above
being satisfied in relation to each such part of the Transaction; and
(iii) to the extent that the Bundeskartellamt retains jurisdiction over any part of
the Transaction, the condition set out in condition (c) above being satisfied in
relation to each such part of the Transaction; and
(iv) to the extent that the Austrian Cartel Court retains jurisdiction over any part
of the Transaction, one of the conditions set out in conditions (d)(i) to (v)
above being satisfied in relation to each such part of the Transaction;
(f) all required filings having been made under the United States Hart-Scott-Rodino Antitrust
Improvements Act of 1976 (as amended) and the rules and regulations thereunder and all
applicable waiting periods with respect thereto having expired or been terminated as
appropriate, in each case in connection with the Transaction;
(g) all necessary notifications and filings required by law or regulation having been made,
all or any applicable waiting and other time periods (including any extensions thereof
(including requests for additional information)) under any applicable legislation or
regulation of any jurisdiction having expired, lapsed or terminated and any approvals or
clearances required by law or regulation having been obtained to the reasonable
satisfaction of UCB as appropriate, in each case, in respect of the Offer, its
implementation and the acquisition of any shares in, or control of, Celltech (or any
member of the Celltech Group) by UCB or any member of the UCB Group and all necessary
statutory and regulatory obligations in connection with the Offer in any jurisdiction
having been complied with;
(h) other than investigations and waiting periods listed in condition (g), no central bank,
government or governmental, quasi-governmental, supranational, statutory or regulatory
body or association, institution or agency (including any trade agency) or any court or
other body (including any professional or environmental body) or person in any
jurisdiction (each a 'Relevant Authority') having decided to take, instituted or
threatened any action, proceeding, suit, investigation, enquiry or reference or enacted,
made or proposed and there not continuing to be outstanding any statute, regulation,
order or decision that would or might reasonably be expected to:
(i) make the Offer, its implementation or the acquisition or the proposed
acquisition of any Celltech Shares (including Celltech Shares represented by
Celltech ADSs) in, or control of, Celltech by any member of the UCB Group void,
unenforceable or illegal or directly or indirectly prohibit or restrict, delay
or interfere with the implementation of, or impose material additional
conditions or obligations with respect to, or otherwise challenge, the Offer,
its implementation or the acquisition of any shares in, or control of, Celltech
by any member of the UCB Group;
(ii) result in a delay in the ability of UCB or any member of the UCB Group, or
render UCB or any member of the UCB Group unable, to acquire all of the Celltech
Shares (including Celltech Shares represented by Celltech ADSs) or require a
divestiture by UCB or any member of the UCB Group of any Celltech Shares
(including Celltech Shares represented by Celltech ADSs);
(iii) require, prevent or materially delay the divestiture (or alter the terms of any
proposed divestiture) by any member of the Wider UCB Group or any member of the
Wider Celltech Group of all or any part of their respective businesses, assets
or properties or impose any limitation on their ability to conduct all or any
part of their respective businesses and to own any of their respective assets or
properties to an extent which is material in the context of the Wider Celltech
Group taken as a whole or the UCB Group taken as a whole (as the case may be);
(iv) impose any material limitation on, or result in any material delay in, the
ability of any member of the UCB Group to acquire or hold Celltech Shares
(including Celltech Shares represented by Celltech ADSs) or other securities (or
the equivalent) in any member of the Celltech Group or to exercise effectively,
directly or indirectly, all or any rights of ownership of Celltech Shares
(including Celltech Shares represented by Celltech ADSs) or other securities (or
the equivalent) in, or to exercise management control over, any member of the
Celltech Group or on the ability of any member of the Celltech Group to hold or
exercise effectively, directly or indirectly, all or any rights of ownership of
shares or other securities (or the equivalent) in, or to exercise management
control over, any other member of the Celltech Group;
(v) result in any member of the Celltech Group ceasing to be able to carry on
business under any name which it presently does so to an extent which is
material in the context of the Wider Celltech Group taken as a whole or the UCB
Group taken as a whole (as the case may be);
(vi) require any member of the UCB Group or of the Celltech Group to acquire or offer
to acquire any shares or other securities (or the equivalent) in any member of
the Celltech Group or any member of the Wider UCB Group owned by any third party
(other than in the implementation of the Offer) to an extent which is material
in the context of the Wider Celltech Group taken as a whole or the UCB Group
taken as a whole (as the case may be);
(vii) impose any limitation on the ability of any member of the Wider UCB Group or the
Celltech Group to integrate or co-ordinate its business, or any part of it, with
the businesses or any part of the businesses of any other member of the Wider
UCB Group and/or the Celltech Group to an extent which is material in the
context of the Wider Celltech Group taken as a whole or the UCB Group taken as a
whole (as the case may be); or
(viii) otherwise adversely affect the business, assets, financial or trading position
or profits or prospects of any member of the Wider UCB Group or of the Wider
Celltech Group in a manner which is adverse to and material in the context of
the UCB Group taken as a whole or the Wider Celltech Group taken as a whole (as
the case may be),
and all applicable waiting and other time periods during which any such Relevant
Authority could decide to take, institute, implement or threaten any such
action, proceeding, suit, investigation, enquiry or reference having expired,
lapsed or been terminated;
(i) all notifications and filings have been made in connection with the Offer and all
authorisations, orders, grants, recognitions, confirmations, licences, consents,
clearances, certificates, permissions and approvals ('Authorisations') necessary or
appropriate in any jurisdiction for, in respect of or resulting from the Offer, its
implementation or the proposed acquisition by UCB or any member of the UCB Group of any
shares in Celltech or control of Celltech (or any member of the Celltech Group) being
obtained in terms and in a form reasonably satisfactory to UCB from appropriate Relevant
Authorities or from any persons or bodies with whom any member of the Wider UCB Group or
the Celltech Group has entered into contractual arrangements and such authorisations,
together with all authorisations necessary or appropriate for any member of the Celltech
Group to carry on its business where such business is material in the context of the
Wider Celltech Group as a whole remaining in full force and effect and no intimation of
any intention to revoke, suspend, restrict or modify or not to renew any such
authorisations having been made;
(j) save as fairly disclosed in the annual report and accounts of the Celltech Group for the
year ended 31 December 2003, or by or on behalf of Celltech to UCB, or as publicly
announced to a Regulatory Information Service by or on behalf of Celltech, (in each such
case) prior to 18 May 2004, there being no provision of any agreement, arrangement,
lease, licence, permit or other instrument to which any member of the Wider Celltech
Group is a party or by or to which any such member or any of its assets is or may be
bound, entitled or subject which, as a result of the making of the Offer, its
implementation or the acquisition or proposed acquisition by UCB of any shares in, or
change in the control or management of, Celltech or otherwise, would or might reasonably
be expected to result in, and no event having occurred which, under any provision of any
agreement, arrangement, licence, permit or other instrument to which any member of the
Wider Celltech Group is a party or by or to which any such member or any of its assets
may be bound, entitled or subject, could reasonably be expected to result in, to an
extent which is, in any case, material in the context of the Wider Celltech Group taken
as a whole:
(i) any monies borrowed by or any other indebtedness (actual or contingent) of
any such member being or becoming repayable or being capable of being
declared repayable immediately or earlier than the stated repayment date or
the ability of such member to borrow monies or incur any indebtedness being
withdrawn or inhibited or any such arrangement, agreement, licence or
instrument relating to any monies borrowed or indebtedness being terminated
or modified or any onerous obligations arising or any action being taken or
arising thereunder;
(ii) the creation or enforcement of any mortgage, charge or other security
interest over the whole or any part of the business, property or assets of
any such member or any such security interest (whenever arising or having
arisen) becoming enforceable;
(iii) any assets or interests of any such member being or falling to be disposed of
or charged or any right arising under which any such asset or interest could
be required to be disposed of or charged other than in the ordinary course of
business;
(iv) the interest or business of any such member in or with any other person, firm
or company (or any agreements or arrangements relating to such interest or
business) being terminated or adversely modified or affected;
(v) any such member ceasing to be able to carry on business under any name under
which it presently does so;
(vi) the value of any such member or its financial or trading position or profits
or prospects being prejudiced or adversely affected;
(vii) any such agreement, arrangement, licence or other instrument being terminated
or adversely modified or any onerous obligation arising or any adverse action
being taken or arising thereunder; or
(viii) the creation of any liabilities (actual or contingent) by any such member;
(k) since 31 December 2003 (except as publicly announced to a Regulatory Information Service
by or on behalf of Celltech before 18 May 2004 or as fairly disclosed in the annual
report and accounts of the Celltech Group for the year ended 31 December 2003, or by or
on behalf of Celltech to UCB prior to 18 May 2004), no member of the Celltech Group
having:
(i) save as between Celltech and its wholly-owned subsidiaries prior to 18 May
2004 or upon the exercise of rights to subscribe for Celltech Shares pursuant
to options granted under the Celltech Share Option Schemes prior to such
date, issued or agreed to issue or authorised the issue of additional shares
of any class, or securities convertible into or exchangeable for, or rights,
warrants or options to subscribe for or acquire, any such shares or
convertible securities;
(ii) recommended, declared, paid or made or proposed to recommend, declare, pay or
make any bonus issue, dividend or other distribution, whether payable in cash
or otherwise, other than a distribution by any wholly-owned subsidiary of
Celltech to Celltech or any of its wholly owned subsidiaries;
(iii) save for transactions between Celltech and its wholly-owned subsidiaries,
implemented or authorised any merger or demerger or acquired or disposed of
or, other than in the ordinary course of business, transferred, mortgaged or
charged, or created any other security interest over, any material asset or
any right, title or interest in any material asset;
(iv) implemented or authorised any reconstruction, amalgamation or scheme of
arrangement;
(v) other than between Celltech and its wholly-owned subsidiaries or between such
wholly-owned subsidiaries, purchased, redeemed or repaid any of its own
shares or other securities or reduced or made or authorised any other change
in its share capital;
(vi) other than between Celltech and its wholly-owned subsidiaries or between such
wholly-owned subsidiaries, made or authorised any change in its loan capital
or issued or authorised the issue of any debentures or incurred or increased
any indebtedness or contingent liability;
(vii) entered into, varied or terminated, or authorised the entry into, variation
or termination of, any contract, commitment, agreement, proposal or
arrangement (whether in respect of capital expenditure or otherwise) which is
outside the ordinary course of trading or which is of a long-term, onerous or
unusual nature or magnitude or which involves or could involve an obligation
of a nature or magnitude which is material in the context of the Wider
Celltech Group (taken as a whole) or which is or is likely to be restrictive
on the business of any member of the Wider Celltech Group or the Wider UCB
Group to an extent which is material in the context of the Wider Celltech
Group or the UCB Group (as appropriate) taken as a whole;
(viii) been unable, or admitted in writing that it is unable, to pay its debts or
having stopped or suspended (or threatened to stop or suspend) payment of its
debts generally or ceased or threatened to cease carrying on all or a
substantial part of its business;
(ix) taken any corporate action or had any legal proceedings started or threatened
against it for its winding-up (voluntary or otherwise), dissolution or
reorganisation (or for any analogous proceedings or steps in any
jurisdiction) or for the appointment of a receiver, administrator,
administrative receiver, trustee or similar officer (or for the appointment
of any analogous person in any jurisdiction) of all or any of its assets and
revenues or appointed any analogous person in any jurisdiction;
(x) waived, compromised or settled any claim which is material;
(xi) entered into or varied the terms of any service agreement or arrangement with
any director or senior executive of Celltech;
(xii) made or consented to any significant change to the terms of the trust deeds
constituting the pension schemes established for its directors and/or
employees and/or their dependants or to the benefits which accrue, or to the
pensions which are payable thereunder, or to the basis on which qualification
for or accrual or entitlement to such benefits or pensions are calculated or
determined, or to the basis upon which the liabilities (including pensions)
of such pension schemes are funded or made, or agreed or consented to any
change to the trustees; or
(xiii) entered into any contract, commitment or arrangement or passed any resolution
or made any offer (which remains open for acceptance) with respect to, or
proposed or announced any intention to effect or propose, any of the
transactions, matters or events referred to in sub-paragraphs (i) to (xii) of
this condition (k);
(l) since 31 December 2003 (except as publicly announced to a Regulatory Information Service
by or on behalf of Celltech before 18 May 2004 or as fairly disclosed in the annual
report and accounts of the Celltech Group for the year ended 31 December 2003, or by or
on behalf of Celltech to UCB prior to 18 May 2004):
(i) no adverse change having occurred in the business, assets, financial or
trading position or profits or prospects of any member of the Wider Celltech
Group to an extent which is material to the Wider Celltech Group taken as a
whole;
(ii) no litigation, arbitration proceedings, prosecution or other legal
proceedings having been threatened, announced, instituted or remaining
outstanding by, against or in respect of any member of the Wider Celltech
Group or to which any member of the Wider Celltech Group is a party (whether
as claimant or defendant or otherwise) and no investigation by any Relevant
Authority or other investigative body against or in respect of any member of
the Celltech Group having been threatened, announced, instituted or remaining
outstanding by, against or in respect of any member of the Wider Celltech
Group which, in any such case, might be reasonably likely to adversely affect
any member of the Wider Celltech Group to an extent which is material to the
Wider Celltech Group (taken as a whole); and
(iii) no contingent or other liability having arisen which would or might be
reasonably likely to adversely affect any member of the Wider Celltech Group
to an extent which is material to the Wider Celltech Group taken as a whole;
(m) except as fairly disclosed to UCB in the annual report and accounts of the Celltech Group
for the year ended 31 December 2003, or by or on behalf of Celltech prior to 18 May 2004,
UCB not having discovered that:
(i) any financial, business or other information concerning the Wider Celltech
Group disclosed at any time by or on behalf of any member of the Wider
Celltech Group is misleading, contains a misrepresentation of fact or omits
to state a fact necessary to make the information contained therein not
misleading and which is material in the context of the Wider Celltech Group
(taken as a whole);
(ii) any member of the Wider Celltech Group is subject to any liability,
contingent or otherwise, which should have been but is not disclosed in the
annual report and accounts of Celltech for the year ended 31 December 2003
and which is material in the context of the Wider Celltech Group (taken as a
whole);
(iii) any past or present member of the Wider Celltech Group has failed to comply
in any material respect with any applicable legislation or regulations of any
jurisdiction or any notice or requirement of any Relevant Authority with
regard to the storage, disposal, discharge, spillage, release, leak or
emission of any waste or hazardous or harmful substance or any substance
likely to impair the environment or harm human or animal health or otherwise
relating to environmental matters or that there has been any such storage,
presence, disposal, discharge, spillage, release, leak or emission (whether
or not the same constituted non-compliance by any person with any such
legislation or regulation, and whenever the same may have taken place), any
of which non-compliance would be likely to give rise to any material
liability (whether actual or contingent) or cost on the part of any member of
the Wider Celltech Group and which is material in the context of the Wider
Celltech Group (taken as a whole); or
(iv) there is, or is reasonably likely to be, any material obligation or liability
(whether actual or contingent) to make good, repair, re-instate or clean up
any property now or previously owned, occupied, operated or made use of or
controlled by any past or present member of the Celltech Group under any
environmental legislation, regulation, notice, circular or order of any
Relevant Authority in any jurisdiction, in each case to an extent which is
material in the context of the Wider Celltech Group (taken as a whole).
If UCB is required by the Panel to make an offer for Celltech Shares under the provisions of Rule
9 of the City Code, then UCB may make such alterations to any of the above conditions as are
necessary to comply with the provisions of that Rule.
UCB reserves the right to waive all or any of conditions (b) to (m) above inclusive, in whole or
in part. The Offer will lapse unless all the above conditions are fulfilled or (if capable of
waiver) waived or, where appropriate, determined by UCB to have been or remain satisfied by 3.00
p.m. (London time), 10.00 a.m. (New York City time) on the twentieth US business day following
the posting of the Offer Document (or such later date as UCB may determine, in accordance with
the City Code and the Exchange Act). UCB shall be under no obligation to waive or treat as
fulfilled any of conditions (b) to (m) inclusive by a date earlier than the latest date for the
fulfilment thereof notwithstanding that the other conditions of the Offer may at such earlier
date have been waived or fulfilled and that there are at such earlier date no circumstances
indicating that any of such conditions may not be capable of fulfilment.
If before 3.00 p.m. (London time), 10.00 a.m. (New York City time) on the twentieth US business
day following the posting of the Offer Document or the date when the Offer becomes unconditional
as to acceptances (whichever is the later):
(i) the OFT has referred the Offer to the Competition Commission; or
(ii) the European Commission has initiated proceedings in respect of the Offer under Article 6
(1)(c) of the Regulation,
the Offer will lapse.
For the purposes of this Appendix:
'Wider Celltech Group' means Celltech and its subsidiary undertakings, associated undertakings
and any other undertakings in which Celltech and such undertakings (aggregating their interests)
have a substantial interest; and
'Wider UCB Group' means UCB and its subsidiary undertakings, associated undertakings and any
other undertakings in which UCB and such undertakings (aggregating their interests) have a
substantial interest.
For these purposes 'subsidiary undertaking', 'associated undertaking' and 'undertaking' have the
meanings given by the Companies Act 1985 (but for these purposes ignoring paragraph 20(1)(b) of
Schedule 4A to the Companies Act 1985) and 'substantial interest' means a direct or indirect
interest in 20 per cent. of more of the equity capital of an undertaking.
APPENDIX II
SOURCES OF INFORMATION AND BASES OF CALCULATION
(a) The value placed by the Offer on the existing share capital of Celltech is based on 278,128,673
Celltech Shares in issue on 17 May 2004.
(b) The closing middle-market prices of Celltech Shares are derived from the London Stock Exchange
Daily Official List for the relevant dates.
(c) Unless otherwise stated, the financial information relating to Celltech is extracted from the
audited financial statements of Celltech for the financial year ended 31 December 2003.
(d) The value as stated in the announcement placed on the existing share capital of UCB is based on
145,933,000 UCB shares in issue on 17 May 2004.
(e) The closing middle-market prices of UCB shares are derived from the Euronext La Cote Officielle
for the relevant dates.
(f) Unless otherwise stated, the financial information relating to UCB is extracted from the audited
financial statements of UCB for the financial year ended 31 December 2003.
Exchange rates
Exchange rates of GBP 1 : USD 1.7675 and GBP 1 : Euro 1.4721 as per Bloomberg at 4.30 p.m.
London time 17th May 2004 have been used throughout this announcement.
APPENDIX III
DEFINITIONS
The following definitions apply throughout this announcement unless the context
otherwise requires:
'Acceptance Condition' the condition as set out in paragraph (a) of Appendix I
to this announcement
'Acceptance Forms' the Form of Acceptance and, in relation to holders of
Celltech ADSs only, the Letter of Transmittal and the
Notice of Guaranteed Delivery, relating to the Offer
'Act' or 'Companies Act' the Companies Act 1985, as amended
'business day' any day, other than a Saturday or Sunday or a public
holiday in the UK, consisting of the time period from
12:01 a.m. until and including 12:00 midnight (London
time)
'Celltech' or the 'Company' Celltech Group plc
'Celltech Group' or the 'Group' Celltech and its subsidiary undertakings and, where the
context permits, each of them
'Celltech ADRs' American Depositary Receipts issued by Celltech under
the deposit agreement representing the right to
Celltech ADSs
'Celltech ADSs' American Depositary Shares, each representing two
Celltech Shares, evidenced by Celltech ADRs
'Celltech Shareholders' holders of Celltech Shares from time to time
'Celltech Share Plans' The Celltech Group plc Sharesave Scheme, the
Chiroscience Group Sharesave Scheme, the Celltech Group
1993 Savings Related Share Option Scheme, the Celltech
Group 1993 Executive Share Option Scheme, the
Chiroscience 1997 All Employee Share Option Scheme, the
Chiroscience Group (No. 1) Executive Share Option
Scheme, the Chiroscience Group (No. 2) Executive Share
Option Scheme, the Darwin Molecular Technologies, Inc.
1993 Stock Option Plan, the Medeva Plc 1996 Executive
Share Option Scheme, the Medeva Plc Executive Share
Option Scheme, the Medeva Plc United States Executive
Stock Option Plan, the Celltech Chiroscience Executive
Share Option Scheme 1999, the Celltech Group plc 2001
Discretionary Share Option Scheme and the Celltech
Deferred Bonus Plan
'Celltech Share(s)' the existing unconditionally allotted or issued and
fully paid ordinary shares of 50 pence each in the
capital of Celltech (including those represented by
Celltech ADSs) and any further such shares which are
unconditionally allotted or issued prior to the time at
which the Offer ceases to be open for acceptance (or,
subject to the provisions of the City Code, such
earlier time and/or date as UCB may decide)
'City Code' The City Code on Takeovers and Mergers
'Directors' or 'Celltech Board' the directors of Celltech
'Euro' euros, the lawful currency of the Euro-zone
'Exchange Act' the United States Securities Exchange Act of 1934 (as
amended) and the rules and regulations promulgated
thereunder
'Form of Acceptance' the form of acceptance, authority and election for use
by Celltech Shareholders in connection with the Offer
'FSA' Financial Services Authority
'JPMorgan' J.P. Morgan plc
'Lazard' Lazard & Co., Limited
'Letter of Transmittal' in relation to Celltech ADSs, the letter of transmittal
relating to the Offer which is being sent with the
Offer Document for use by holders of Celltech ADSs
wishing to accept the Offer
'LIBOR' the interest rate offered in the market for London
inter-bank six month sterling deposits on the first
business day of the relevant interest period which
appears on the Telerate page 3750 at or about 11:00
a.m. on the same date
'Loan Note Alternative' the alternative under the Offer whereby Celltech
Shareholders (other than certain Overseas Shareholders)
who validly accept the Offer may elect to receive Loan
Notes instead of all or part of the cash consideration
to which they would otherwise have been entitled under
the Offer
'Loan Notes' the loan notes of UCB to be issued pursuant to the Loan
Note Alternative
'London Stock Exchange' London Stock Exchange plc
'Morgan Stanley' Morgan Stanley & Co. Limited
'Morgan Stanley Group' Morgan Stanley Dean Witter & Co. and its affiliates
'New York Stock Exchange' or 'NYSE' New York Stock Exchange, Inc.
'Notice of Guaranteed Delivery' the notice of guaranteed delivery relating to the Offer
for use by holders of Celltech ADSs, which will
accompany the Offer Document
'Offer' the recommended cash offer to be made by UCB and
outside the United States by Lazard on its behalf to
acquire the whole of the issued and to be issued share
capital of Celltech, on the terms and subject to the
conditions to be set out in the Offer Document and the
Acceptance Forms including, where the context so
requires, any subsequent revision, variation, extension
or renewal of such offer
'Offer Document' the document containing and setting out the terms and
conditions of the Offer to be sent to Celltech
Shareholders
'Official List' the Official List of the UK Listing Authority
'Overseas Celltech Shareholders' Celltech Shareholders who are resident in or nationals
or citizens of jurisdictions outside the United Kingdom
or United States or who are nominees of, or custodians
or trustees for, citizens or nationals of other
countries
'Panel' the Panel on Takeovers and Mergers
'SEC' the United States Securities and Exchange Commission
'Securities Act' the United States Securities Act of 1933 (as amended)
and the rules and regulations promulgated thereunder
'Sterling' or 'GBP' pounds sterling, the lawful currency of the United
Kingdom
'UCB' UCB S.A.
'UCB Group' UCB and its subsidiary undertakings and, where the
context admits, each of them
'UCB Shares' the shares of UCB S.A.
'UK' or 'United Kingdom' United Kingdom of Great Britain and Northern Ireland
'UK Listing Authority' the FSA acting in its capacity as the competent
authority for listing under Part VI of the Financial
Services and Markets Act 2000
'United States' or 'US' the United States of America, its territories and
possessions, any State of the United States of America
and the District of Columbia
'US business days' any day, other than Saturday, Sunday or a federal
holiday in the United States and consisting of the time
period from 12:01 am to 12:00 midnight Eastern (US)
time
'US dollar' or 'USD' the lawful currency of the United States
'US Person' a US person as defined in Regulation S under the
Securities Act
All times referred to are London time unless otherwise stated.
This information is provided by RNS
The company news service from the London Stock Exchange
|
